Sensitivity of human malignant intracranial tumors against MCNU in vitro in comparison to ACNU and BCNU

An in vitro chemosensitivity test was carried out in 50 specimen of human malignant intracranial tumors. Aim of the study was to evaluate the proportion of sensitivity against MCNU (Ranomustine) in comparison to ACNU and BCNU. 47 tests were evaluable. Mean viability of the specimen was 83.3 +/- 18.7...

Full description

Saved in:
Bibliographic Details
Published inJournal of neuro-oncology Vol. 8; no. 1; p. 41
Main Authors Tonn, J C, Schönmayr, R, Kraemer, H P
Format Journal Article
LanguageEnglish
Published United States 01.02.1990
Subjects
Aged
Antineoplastic Agents - pharmacology
Antineoplastic Agents - therapeutic use
Astrocytoma - drug therapy
Brain Neoplasms - drug therapy
Carmustine - pharmacology
Carmustine - therapeutic use
Drug Screening Assays, Antitumor
Female
Glioma - drug therapy
Humans
Male
Middle Aged
Nimustine - pharmacology
Nimustine - therapeutic use
Nitrosourea Compounds - pharmacology
Nitrosourea Compounds - therapeutic use
Tumor Cells, Cultured - drug effects
Online AccessGet more information

Cover

More Information
Summary:An in vitro chemosensitivity test was carried out in 50 specimen of human malignant intracranial tumors. Aim of the study was to evaluate the proportion of sensitivity against MCNU (Ranomustine) in comparison to ACNU and BCNU. 47 tests were evaluable. Mean viability of the specimen was 83.3 +/- 18.7%, mean plating efficiency was 0.068 +/- 0.051%. 9/47 settings revealed sensitivity against MCNU in vitro (ACNU: 10/47; BCNU: 16/46). There was no advantage of MCNU concerning age or sex of the patients. Brain metastases seemed to be slightly more frequent sensitive against MCNU than primary brain tumors. Cross resistance between ACNU, BCNU and MCNU was rather high. The results of this in vitro series do not encourage a clinical trial of MCNU as an alternative to the commonly used nitrosoureas.
ISSN:0167-594X
DOI:10.1007/BF00182085